NCT06851299View on ClinicalTrials.gov

The Clinical Study of the Efficacy and Safety of Trop2-ADC Monotherapy or Combination Immunotherapy Strategy in the Treatment of Advanced Triple-negative Breast Cancer.

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 1, 2025

Primary Completion Date

April 30, 2027

Study Completion Date

February 29, 2028

Conditions
Metastatic Triple-negative Breast Cancer
Interventions
DRUG

trop2-ADC

Accept ADC monotherapy

DRUG

ADC +anti-angiogenic drug

Accept ADC combined with anti-angiogenic drug

DRUG

ADC + PD1 monoclonal antibody +anti-angiogenic drug

ADC combined with PD1 monoclonal antibody and anti-angiogenic drug

Trial Locations (1)

510000

RECRUITING

Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China;, Guangzhou

All Listed Sponsors
lead

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

OTHER